Dexras1 Induces Dysdifferentiation of Oligodendrocytes and Myelin Injury by Inhibiting the cAMP-CREB Pathway after Subarachnoid Hemorrhage

Yuanjun Xin, Jie Chen, Hongxia Zhang, Robert P. Ostrowski, Yidan Liang, Jun Zhao, Xiang Xiang, Fuming Liang, Wenqiao Fu, Hao Huang, Xintong Wu, Jun Su, Jiewen Deng, Zhaohui HeCells 2022 · DOI

TL;DR

This study reveals that Dexras1, a protein whose levels surge after subarachnoid hemorrhage (SAH), exacerbates white matter damage by disrupting oligodendrocyte development. The researchers found that Dexras1 inhibits the crucial cAMP-CREB signaling pathway, leading to myelin injury and impaired oligodendrocyte differentiation, offering a potential new therapeutic target for SAH recovery.

What Problem Does This Paper Address?

Subarachnoid hemorrhage (SAH) is a severe neurological event with high mortality and disability. While neuronal damage is a known consequence, white matter damage (WMD), characterized by myelin injury and oligodendrocyte dysfunction, is increasingly recognized as a significant contributor to neurological deficits after SAH. However, the precise molecular mechanisms driving this WMD remain unclear. This paper investigates the role of Dexras1, a protein previously implicated in other neurological conditions, in the context of SAH-induced WMD, aiming to uncover its contribution to oligodendrocyte dysdifferentiation and myelin damage.

Methods

The researchers employed a multi-pronged approach using both in vivo and in vitro models.

  • In Vivo SAH Model: They established a rat model of SAH through endovascular perforation. To manipulate Dexras1 levels, they used lentiviral vectors for either overexpression (SAH+LV-Dexras1+) or knockdown (SAH+LV-Dexras1-) of Dexras1.
  • In Vitro SAH Model: Primary cortical neurons were treated with oxyhemoglobin (OxyHb) to mimic SAH conditions. Oligodendrocyte precursor cells (OPCs) were cultured and differentiated.
  • Key Techniques:
    • Western Blotting (WB): Used to quantify protein levels of Dexras1, myelin markers (MBP, CNPase), OPC markers (NG2), glial activation markers (GFAP, Iba-1), and signaling pathway components (CREB, pCREB).
  • Immunofluorescence (IF): Employed to visualize the cellular localization of Dexras1 and to assess the expression and distribution of OPCs and mature oligodendrocytes.
  • Transmission Electron Microscopy (TEM): Utilized to examine the ultrastructural integrity of myelin sheaths and axons.
  • Neurobehavioral Testing: The Morris Water Maze (MWM) was used to evaluate spatial learning and memory deficits.
  • ELISA: Used to measure inflammatory cytokine levels (TNF-α, IL-1β).
  • 8-Bromo-cAMP: Introduced as an activator of the cAMP-CREB pathway to investigate its interaction with Dexras1.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • Dexras1 as a Key Player in SAH-induced WMD: The study strongly implicates Dexras1 as a significant contributor to white matter damage following SAH, moving beyond its previously known roles.
  • Inhibition of cAMP-CREB Pathway: A crucial finding is that Dexras1 directly inhibits the cAMP-CREB signaling pathway, which is vital for oligodendrocyte differentiation and survival. This provides a mechanistic link between Dexras1 and WMD.
  • Early Intervention Potential: The observed acute onset of OPC differentiation disorder after SAH, and the potential for improvement with Dexras1 knockdown, suggests that early therapeutic interventions targeting Dexras1 could be beneficial.
  • Inflammation and OPC Differentiation Link: The study reinforces the connection between inflammatory factors (TNF-α, IL-1β) and impaired OPC differentiation, suggesting a complex interplay in SAH pathology.

Key Results

  • Dexras1 Upregulation in SAH: Dexras1 protein levels were significantly increased in the brain 24 hours after SAH induction.
  • Dexras1 Overexpression Worsens WMD: Overexpressing Dexras1 in vivo exacerbated myelin damage, reduced mature oligodendrocyte markers (CNPase), and increased OPC markers (NG2). This was accompanied by worsened neurological deficits and increased brain edema.
  • Dexras1 Knockdown Ameliorates WMD: Conversely, reducing Dexras1 levels (knockdown) protected against myelin injury, improved OPC differentiation, reduced glial activation, and improved neurological function and brain edema.
  • Inhibition of cAMP-CREB: In vitro experiments showed that Dexras1 overexpression inhibited CREB and pCREB phosphorylation, key components of the cAMP-CREB pathway, while Dexras1 knockdown had the opposite effect.
  • Myelin Damage and OPC Dysdifferentiation: Both in vivo and in vitro models demonstrated significant myelin sheath damage and impaired differentiation of oligodendrocyte precursor cells following SAH, with Dexras1 playing a modulating role.

Limitations and Future Work

The authors acknowledge several limitations and suggest future research directions:

  • Direct Link Between Inflammation and WMD: While a correlation was observed, further studies are needed to establish a direct causal relationship between inflammation, OPC differentiation disorder, and myelin damage.
  • Mechanisms of Cell Death: The study focused on WMD. Future research should explore how Dexras1 mediates other cell death pathways relevant to SAH, such as apoptosis, ferroptosis, and pyroptosis.
  • Therapeutic Strategies: The findings suggest that targeting Dexras1 or the cAMP-CREB pathway could be a viable therapeutic strategy for SAH. Further investigation into anti-inflammatory interventions and other cell-based therapies for OPC differentiation disorders is warranted.

Summary updated

Abstract

White matter damage (WMD), one of the research hotspots of subarachnoid hemorrhage (SAH), mainly manifests itself as myelin injury and oligodendrocyte differentiation disorder after SAH, although the specific mechanism remains unclear. Dexamethasone-induced Ras-related protein 1(Dexras1) has been reported to be involved in nervous system damage in autoimmune encephalitis and multiple sclerosis. However, whether Dexras1 participates in dysdifferentiation of oligodendrocytes and myelin injury after SAH has yet to be examined, which is the reason for creating the research content of this article. Here, intracerebroventricular lentiviral administration was used to modulate Dexras1 levels in order to determine its functional influence on neurological injury after SAH. Immunofluorescence, transmission electron microscopy, and Western blotting methods, were used to investigate the effects of Dexras1 on demyelination, glial cell activation, and differentiation of oligodendrocyte progenitor cells (OPCs) after SAH. Primary rat brain neurons were treated with oxyhemoglobin to verify the association between Dexras1 and cAMP-CREB. The results showed that Dexras1 levels were significantly increased upon in vivo SAH model, accompanied by OPC differentiation disturbances and myelin injury. Dexras1 overexpression significantly worsened OPC dysdifferentiation and myelin injury after SAH. In contrast, Dexras1 knockdown ameliorated myelin injury, OPC dysdifferentiation, and glial cell activation. Further research of the underlying mechanism discovered that the cAMP-CREB pathway was inhibited after Dexras1 overexpression in the in vitro model of SAH. This study is the first to confirm that Dexras1 induced oligodendrocyte dysdifferentiation and myelin injury after SAH by inhibiting the cAMP-CREB pathway. This present research may reveal novel therapeutic targets for the amelioration of brain injury and neurological dysfunction after SAH.
BibTeX
@inproceedings{xin2022dexras,
  author = {Yuanjun Xin and Jie Chen and Hongxia Zhang and Robert P. Ostrowski and Yidan Liang and Jun Zhao and Xiang Xiang and Fuming Liang and Wenqiao Fu and Hao Huang and Xintong Wu and Jun Su and Jiewen Deng and Zhaohui He},
  title = {{Dexras1 Induces Dysdifferentiation of Oligodendrocytes and Myelin Injury by Inhibiting the cAMP-CREB Pathway after Subarachnoid Hemorrhage}},
  booktitle = {Cells},
  year = {2022},
  doi = {10.3390/cells11192976},
}
Figure